Search details
1.
Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss.
J Pathol
; 253(3): 292-303, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33166087
2.
Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.
Proc Natl Acad Sci U S A
; 116(2): 631-640, 2019 01 08.
Article
in English
| MEDLINE | ID: mdl-30578319
3.
Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.
Cancer
; 123(21): 4130-4138, 2017 Nov 01.
Article
in English
| MEDLINE | ID: mdl-28700821
4.
The fat side of prostate cancer.
Biochim Biophys Acta
; 1831(10): 1518-32, 2013 Oct.
Article
in English
| MEDLINE | ID: mdl-23562839
5.
Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition.
Sci Signal
; 17(831): eadh1922, 2024 Apr 09.
Article
in English
| MEDLINE | ID: mdl-38593154
6.
Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors.
Proc Natl Acad Sci U S A
; 107(18): 8352-6, 2010 May 04.
Article
in English
| MEDLINE | ID: mdl-20404174
7.
Lactate as Key Metabolite in Prostate Cancer Progression: What Are the Clinical Implications?
Cancers (Basel)
; 15(13)2023 Jul 03.
Article
in English
| MEDLINE | ID: mdl-37444583
8.
The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer.
Mol Cancer Res
; 21(3): 253-260, 2023 03 01.
Article
in English
| MEDLINE | ID: mdl-36511902
9.
MetChem: a new pipeline to explore structural similarity across metabolite modules.
Bioinform Adv
; 3(1): vbad053, 2023.
Article
in English
| MEDLINE | ID: mdl-37424942
10.
Metabolic alterations and targeted therapies in prostate cancer.
J Pathol
; 223(2): 283-94, 2011 Jan.
Article
in English
| MEDLINE | ID: mdl-21125681
11.
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.
Nat Commun
; 13(1): 2559, 2022 05 13.
Article
in English
| MEDLINE | ID: mdl-35562350
12.
Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer.
Cancer Drug Resist
; 4(1): 143-162, 2021.
Article
in English
| MEDLINE | ID: mdl-35582011
13.
Prostate Cancer Progression: as a Matter of Fats.
Front Oncol
; 11: 719865, 2021.
Article
in English
| MEDLINE | ID: mdl-34386430
14.
Exploring a role for fatty acid synthase in prostate cancer cell migration.
Small GTPases
; 12(4): 265-272, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33043786
15.
Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum.
Mol Cancer Res
; 19(3): 475-484, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33168599
16.
ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer.
Cancer Res
; 81(7): 1704-1718, 2021 04 01.
Article
in English
| MEDLINE | ID: mdl-33547161
17.
Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases.
Oncogene
; 39(18): 3666-3679, 2020 04.
Article
in English
| MEDLINE | ID: mdl-32139877
18.
When fat goes down, prostate cancer is on the ropes.
Mol Cell Oncol
; 6(3): 1595308, 2019.
Article
in English
| MEDLINE | ID: mdl-31131311
19.
Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging.
Mol Cancer Res
; 17(5): 1155-1165, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30745465
20.
Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.
Mol Cancer Res
; 17(2): 446-456, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30333152